The company raises EUR 540,000 (USD 738, 000) from historical shareholders to expand its staff Rhenovia, the world leader in biosimulation of the central nervous system, plans to raise a further EUR 2 million in 2014 to step up development in its three key markets of medicinal products, agrifood and neurotoxicity
Rhenovia Pharma secures Series B funding
This entry was posted in Non classé. Bookmark the permalink. Both comments and trackbacks are currently closed.
